Achieve Life Sciences Inc
$ 5.13
-3.02%
05 Jun - close price
- Market Cap 532,801,000 USD
- Current Price $ 5.13
- High / Low $ 5.30 / 5.00
- Stock P/E N/A
- Book Value 0.20
- EPS -1.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.08 %
- ROE -4.96 %
- 52 Week High 6.15
- 52 Week Low 2.00
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$13.11
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-24 | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-11 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-14 |
| Reported EPS | -0.19 | -0.28 | -0.28 | -0.37 | -0.37 | -0.36 | -0.36 | -0.25 | -0.26 | -0.26 | -0.34 | -0.43 |
| Estimated EPS | -0.2986 | -0.2771 | -0.24 | -0.37 | -0.3657 | -0.36 | -0.26 | -0.23 | -0.24 | -0.31 | -0.38 | -0.42 |
| Surprise | 0.1086 | -0.0029 | -0.04 | 0 | -0.0043 | 0 | -0.1 | -0.02 | -0.02 | 0.05 | 0.04 | -0.01 |
| Surprise Percentage | 36.3697% | -1.0466% | -16.6667% | 0% | -1.1758% | 0% | -38.4615% | -8.6957% | -8.3333% | 16.129% | 10.5263% | -2.381% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHV
2026-06-03 09:09:49
Achieve Life Sciences has appointed Jeffrey Farrow and Reid Waldman, MD to its Board of Directors to bolster the company's commercial strategy, clinical, and finance expertise. These appointments come as Achieve prepares for the potential approval and launch of cytisinicline, a treatment for nicotine dependence. Both Farrow and Waldman bring extensive experience in biopharmaceutical commercialization, financing, and clinical development.
2026-06-02 20:18:55
ACHIEVE Life Sciences, Inc. director Reid Alexander Waldman filed an initial Form 3, indicating no beneficial ownership of the company's securities with 0 shares held directly. This filing establishes his baseline holdings as he becomes a reporting insider, offering transparency rather than signaling a new transaction. The Form 3 details his directorship and confirms no direct or indirect beneficial ownership of non-derivative or derivative securities.
2026-06-02 20:18:55
Achieve Life Sciences director Reid Alexander Waldman was granted 47,250 stock options with an exercise price of $5.24 per share. These options will vest in equal monthly installments over 36 months starting May 29, 2026, and will expire on May 29, 2036. This transaction is considered standard compensation and not an open-market trade.
2026-06-02 20:18:55
Achieve Life Sciences director Jeffrey S. Farrow has filed an initial Form 3 with the SEC, reporting no beneficial ownership of the company's securities. This filing establishes a baseline of zero shares for Farrow as a director, serving as an initial disclosure of his ownership status. The Form 3 indicates that Farrow currently holds no shares, and no buy or sell transactions were reported.
2026-06-02 20:18:55
Achieve Life Sciences (ACHV) director Jeffrey S. Farrow was granted 47,250 stock options with an exercise price of $5.24 per share, expiring on May 29, 2036. The options will vest in equal monthly installments over 36 months, beginning May 29, 2026, provided he continues to offer services to the company. This grant increases his total option holdings to 47,250 shares.
2026-06-02 13:10:18
Achieve Life Sciences, Inc. (ACHV) announced the appointment of Jeff Farrow and Reid Waldman, M.D., to its Board of Directors, effective May 29, 2026. Both will hold key committee leadership roles, including chairing the Audit and Compensation Committees. The new directors will receive a pro-rated annual cash retainer of $40,000, additional cash compensation for committee service, and stock options to purchase 47,250 shares of common stock, vesting monthly over three years.
